Ironwood Pharmaceuticals and Allergan have received FDA approval for a 72 mcg dose of Linzess for the treatment of chronic idiopathic constipation in adult patients.

Linzess is now FDA-approved in three dosage strengths: 290 mcg for adult patients with irritable bowel syndrome with constipation, as well as 145 mcg and 72 mcg for the treatment of adults with CIC.

The new dose is expected to be available in the first quarter of 2017.